Table 2.

Cumulative proportion % of new incident and persistent HPV infections by agea

Cumulative proportion % of new incident infections (95% CI)Cumulative proportion % of new persistent infections (95% CI)
Women ages 15 to 26 years (protocol 13)Women ages 24 to 34 years (protocol 019)Women ages 35 to 45 years (protocol 019)Women ages 15 to 26 years (protocol 13)Women ages 24 to 34 years (protocol 019)Women ages 35 to 45 years (protocol 019)
N = 1,049aN = 473aN = 515aN = 1,049aN = 473aN = 515a
HPV type
64.5 (2.3–8.4)b6.3 (4.3–9.1)2.1 (1.1–4.0)2.9 (0.5–14.8)b2.4 (1.4–4.3)0.9 (0.3–2.3)
110.9 (0.2–4.5)b0.9 (0.3–2.3)0.4 (0.1–1.7)0.5 (0.07–3.6)b0.4 (0.1–1.8)0.0 (—)
1623.8 (20.5–27.5)8.7 (6.4–11.7)3.6 (2.2–6.0)15.1 (12.0–18.9)6.35 (4.25–9.4)1.8 (0.9–3.4)
189.0 (6.8–11.9)2.40 (1.3–4.3)3.0 (1.6–5.7)4.2 (3.0–5.7)1.99 (0.96–4.1)0.8 (0.3–2.1)
3110.7 (8.6–13.4)2.60 (1.4–4.7)1.4 (0.7–3.0)7.1 (5.1–10.1)1.9 (0.96–3.9)0.5 (0.1–2.0)
333.4 (2.4–4.9)1.8 (0.9–3.5)0.6 (0.2–1.8)2.1 (1.4–3.3)0.66 (0.2–2.0)0.0 (—)
355.0 (3.2–7.9)2.2 (1.1–4.2)1.6 (0.8–3.1)2.1 (1.2–3.5)1.1 (0.39–3.1)0.4 (0.1–1.6)
39NTc4.0 (2.5–6.4)4.1 (2.4–6.7)NTc1.8 (0.9–3.6)1.6 (0.8–3.2)
455.1 (3.6–7.3)2.9 (1.6–5.3)1.9 (0.9–4.0)2.6 (1.8–3.9)0.7 (0.2–2.0)0.6 (0.2–1.9)
51NTc8.4 (6.1–11.6)4.5 (2.8–7.2)NTc4.9 (3.1–7.6)1.5 (0.7–3.1)
5214.7 (11.5–18.7)3.8 (2.36–6.0)3.8 (2.3–6.2)7.4 (5.4–10.1)1.8 (0.9–3.5)1.6 (0.8–3.2)
56NTc11.1 (8.4–14.7)7.1 (5.0–9.8)NTc4.3 (2.7–6.6)2.5 (1.4–4.4)
587.8 (6.1–9.9)3.7 (2.2–5.9)2.5 (1.4–4.4)5.8 (3.8–8.9)1.1 (0.5–2.6)1.3 (0.4–4.3)
5913.3 (10.4–17.1)2.9 (1.7–4.9)2.5 (1.4–4.7)5.3 (4.0–7.0)1.6 (0.7–3.2)1.0 (0.4–2.4)
Any of the nonvaccine types
35/59c35/39/51/56/5935/39/51/56/5935/59c35/39/51/56/59)35/39/51/56/59
17.2 (13.7–21.4)c21.1 (17.4–25.5)14.6 (11.7–18.2)7.2 (5.6–9.3)c11.0 (8.3–14.5)6.2 (4.3–8.7)
Any of the qHPV vaccine types
16/18b6/11/16/186/11/16/1816/18b6/11/16/186/11/16/18
28.5 (24.9–32.5)b15.9 (12.9–19.7)8.2 (5.8–11.6)18.3 (15.1–22.2)b10.5 (7.8–14.1)3.3 (2.0–5.3)
Any of the 9vHPV vaccine types
16/18/31/33/45/52/58b6/11/16/18/31/33/45/52/586/11/16/18/31/33/45/52/5816/18/31/33/45/52/58 b6/11/16/18/31/33/45/52/586/11/16/18/31/33/45/52/58
41.9 (38.2–45.8)b24.1 (20.3–28.4)15.3 (12.1–19.3)29.0 (25.5–32.9)b14.3 (11.2–18.2)6.49 (4.44–9.44)
Any of the high-risk vaccine types (16/18/31/33/45/52/58)
41.9 (38.2–45.8)19.9 (16.5–24.0)13.9 (10.9–17.8)29.1 (25.5–32.9)12.1 (9.2–15.9)6.07 (4.09–8.98)
  • aAnalyses for incident and persistent infection were restricted to placebo recipients who were seronegative to HPV6/11/16/18, DNA negative for the 14 tested HPV types, and had a normal Pap test result at day 1, as denoted by the N's in the header rows. Persistent infection was defined as detection of a new HPV genital infection in follow-up genital swabs collected on at least 2 consecutive visits spaced at least 6 months apart.

  • bIn protocol 013, swabs were not tested for HPV types 6 and 11 after month 7; therefore, the average follow-up for cumulative incidence of infection is 18 months for 6/11, vs 48 months for all other HPV types. HPV6/11 are not included in the cumulative incidence estimates for the qHPV vaccine types and the 9vHPV vaccine types.

  • cIn protocol 013, swabs were not tested (NT) for HPV39/51/56 after day 1. HPV39/51/56 are not included in the cumulative incidence estimates for the nonvaccine types.